UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Kinetics of myelin breakdown products: A labeling study in patients with progressive multiple sclerosis

Clinical and translational science, 2022-03, Vol.15 (3), p.638-648

2022

Volltextzugriff (PDF)

Amygdala abnormalities in first-degree relatives of individuals with schizophrenia unmasked by benzodiazepine challenge

Psychopharmacologia, 2011-12, Vol.218 (3), p.503-512

2011

Volltextzugriff (PDF)

Brain corticotropin-releasing hormone (CRH) circuits in the developing rat: Effect of maternal deprivation

Brain research, 2006-11, Vol.1121 (1), p.83-94

2006

Volltextzugriff (PDF)

GABAergic circuits and the stress hyporesponsive period in the rat: Ontogeny of glutamic acid decarboxylase (GAD) 67 mRNA expression in limbic–hypothalamic stress pathways

Brain research, 2007-03, Vol.1138, p.1-9

2007

Volltextzugriff (PDF)

Update to: Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease

The Journal of Prevention of Alzheimer's Disease, 2024, Vol.11 (4), p.1178-1179

2024

Volltextzugriff (PDF)

Differential Expression of c-fos and Tyrosine Hydroxylase mRNA in the Adrenal Gland of the Infant Rat: Evidence for an Adrenal Hyporesponsive Period

Endocrinology (Philadelphia), 2002-05, Vol.143 (5), p.1717-1725

2002

Volltextzugriff (PDF)

Reductions in Biomarkers of Alzheimer’s Disease Pathophysiology Following Treatment With Aducanumab Were Associated With Slowing in Clinical Decline (P1-1.Virtual)

Neurology, 2022-05, Vol.98 (18_supplement)

2022

Volltextzugriff (PDF)

CSF biomarker concordance with amyloid PET in Phase 3 studies of aducanumab

Alzheimer's & dementia, 2023-08, Vol.19 (8), p.3379-3388

2023

Volltextzugriff (PDF)

Concordance of CSF biomarkers with amyloid PET at baseline in EMERGE/ENGAGE, phase 3 studies of aducanumab in patients with early Alzheimer’s disease

Alzheimer's & dementia, 2022-12, Vol.18 (S6), p.n/a

2022

Volltextzugriff (PDF)

Reductions in biomarkers of Alzheimer’s disease pathophysiology following treatment with aducanumab were associated with slowing in clinical decline

Alzheimer's & dementia, 2021-12, Vol.17 (S4), p.n/a

2021

Volltextzugriff (PDF)

Tau positron emission tomography, cerebrospinal fluid and plasma biomarkers of neurodegeneration, and neurocognitive testing: an exploratory study of participants with myotonic dystrophy type 1

Journal of neurology, 2022-07, Vol.269 (7), p.3579-3587

2022

Volltextzugriff (PDF)

Stress-Induced Alterations in Corticotropin-Releasing Hormone and Vasopressin Gene Expression in the Paraventricular Nucleus during Ontogeny

Neuroendocrinology, 2000-06, Vol.71 (6), p.333-342

2000

Volltextzugriff (PDF)

Maternal deprivation increases cell death in the infant rat brain

Brain research. Developmental brain research, 2002-01, Vol.133 (1), p.1-11

2002

Volltextzugriff (PDF)

Brief assessment of cognitive function in myotonic dystrophy: Multicenter longitudinal study using computer‐assisted evaluation

Muscle & nerve, 2022-05, Vol.65 (5), p.560-567

2022

Volltextzugriff (PDF)

Emerge and Engage topline results: Phase 3 studies of aducanumab in early Alzheimer’s disease

Alzheimer's & dementia, 2020-12, Vol.16, p.n/a

2020

Volltextzugriff (PDF)

Emerge and Engage topline results: Phase 3 studies of aducanumab in early Alzheimer’s disease: Developments in clinical trials and cognitive assessment

Alzheimer's & dementia, 2020-12, Vol.16 (S9)

2020

Volltextzugriff (PDF)

Skin Blood Flow Measured By LSCI Demonstrates Treatment Effect of Chronic Transfusion Protocol in Sickle Cell Disease

Blood, 2016-12, Vol.128 (22), p.4871-4871

2016

Volltextzugriff (PDF)

Gene expression profiling in the amygdala: An approach to examine the molecular substrates of mammalian behavior

Physiology & behavior, 2001-08, Vol.73 (5), p.841-847

2001

Volltextzugriff (PDF)

EMERGE et ENGAGE : premiers résultats des études de phase III sur l’aducanumab dans la maladie d’Alzheimer au stade précoce

Revue neurologique, 2021-04, Vol.177, p.S2-S2

2021

Volltextzugriff (PDF)

P50 amplitude reduction: a nicotinic receptor-mediated deficit in first-degree relatives of schizophrenia patients

Psychopharmacologia, 2012-05, Vol.221 (1), p.39-52

2012

Volltextzugriff (PDF)

Workshop Report: consensus on biomarkers of cerebral involvement in myotonic dystrophy, 2–3 December 2014, Milan, Italy

Neuromuscular disorders : NMD, 2015-10, Vol.25 (10), p.813-823

2015

Volltextzugriff (PDF)

Consensus on cerebral involvement in myotonic dystrophy: workshop report: May 24-27, 2013, Ferrere (AT), Italy

Neuromuscular disorders : NMD, 2014-05, Vol.24 (5), p.445-452

2014

Volltextzugriff (PDF)

The ontogeny of the neuroendocrine response to endotoxin

Brain research. Developmental brain research, 1999-10, Vol.117 (1), p.21-29

1999

Volltextzugriff (PDF)

The acetylcholine release enhancer linopirdine induces Fos in neocortex of aged rats

Neurobiology of aging, 2001-05, Vol.22 (3), p.485-494

2001

Volltextzugriff (PDF)

1 – 25 von 40

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(39)
Dissertationen
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(25)
Science & Technology
(25)
Neurosciences & Neurology
(22)
Neurosciences
(19)
Animals
(17)
Male
(14)
Female
(12)
Humans
(11)
Rats
(11)
Biological And Medical Sciences
(10)
Rats, Sprague-Dawley
(9)
Clinical Neurology
(8)
Maternal Deprivation
(7)
Rats, Long-Evans
(7)
Psychology. Psychoanalysis. Psychiatry
(6)
Stress
(6)
Adult
(5)
Fundamental And Applied Biological Sciences. Psychology
(5)
Medical Sciences
(5)
Neurology
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Kinetics of myelin breakdown products: A labeling study in patients with progressive multiple sclerosis

Amygdala abnormalities in first-degree relatives of individuals with schizophrenia unmasked by benzodiazepine challenge

Brain corticotropin-releasing hormone (CRH) circuits in the developing rat: Effect of maternal deprivation

GABAergic circuits and the stress hyporesponsive period in the rat: Ontogeny of glutamic acid decarboxylase (GAD) 67 mRNA expression in limbic–hypothalamic stress pathways

Update to: Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease

Differential Expression of c-fos and Tyrosine Hydroxylase mRNA in the Adrenal Gland of the Infant Rat: Evidence for an Adrenal Hyporesponsive Period

Reductions in Biomarkers of Alzheimer’s Disease Pathophysiology Following Treatment With Aducanumab Were Associated With Slowing in Clinical Decline (P1-1.Virtual)

CSF biomarker concordance with amyloid PET in Phase 3 studies of aducanumab

Concordance of CSF biomarkers with amyloid PET at baseline in EMERGE/ENGAGE, phase 3 studies of aducanumab in patients with early Alzheimer’s disease

Reductions in biomarkers of Alzheimer’s disease pathophysiology following treatment with aducanumab were associated with slowing in clinical decline

Tau positron emission tomography, cerebrospinal fluid and plasma biomarkers of neurodegeneration, and neurocognitive testing: an exploratory study of participants with myotonic dystrophy type 1

Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1/2a trial

Stress-Induced Alterations in Corticotropin-Releasing Hormone and Vasopressin Gene Expression in the Paraventricular Nucleus during Ontogeny

Maternal deprivation increases cell death in the infant rat brain

Brief assessment of cognitive function in myotonic dystrophy: Multicenter longitudinal study using computer‐assisted evaluation

Emerge and Engage topline results: Phase 3 studies of aducanumab in early Alzheimer’s disease

Emerge and Engage topline results: Phase 3 studies of aducanumab in early Alzheimer’s disease: Developments in clinical trials and cognitive assessment

Skin Blood Flow Measured By LSCI Demonstrates Treatment Effect of Chronic Transfusion Protocol in Sickle Cell Disease

Gene expression profiling in the amygdala: An approach to examine the molecular substrates of mammalian behavior

EMERGE et ENGAGE : premiers résultats des études de phase III sur l’aducanumab dans la maladie d’Alzheimer au stade précoce

P50 amplitude reduction: a nicotinic receptor-mediated deficit in first-degree relatives of schizophrenia patients

Workshop Report: consensus on biomarkers of cerebral involvement in myotonic dystrophy, 2–3 December 2014, Milan, Italy

Consensus on cerebral involvement in myotonic dystrophy: workshop report: May 24-27, 2013, Ferrere (AT), Italy

The ontogeny of the neuroendocrine response to endotoxin

The acetylcholine release enhancer linopirdine induces Fos in neocortex of aged rats

Suchergebnisse filtern